UroGen Pharma Income Statement (2016-2026) | URGN

Income Statement Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
11.35M16.17M13.56M16.60M16.10M18.09M17.19M21.14M20.85M23.53M18.78M21.85M25.20M24.57M20.25M24.21M27.48M37.84M50.96M72.46M
Cost of Revenue (Quarter)
1.24M1.59M1.52M1.85M2.02M2.26M2.27M2.44M2.37M2.29M1.73M2.23M2.45M2.47M2.33M3.55M3.28M3.29M4.14M6.57M
Gross Profit (Quarter)
10.11M14.59M12.04M14.76M14.08M15.83M14.93M18.70M18.48M21.24M17.05M19.62M22.75M22.09M17.92M20.66M24.20M34.55M46.82M65.88M
Operating items
Research & Development (Quarter)
11.92M13.08M12.70M12.64M13.09M14.48M12.50M11.58M10.23M11.30M15.49M15.40M11.36M14.89M19.87M18.91M14.01M14.31M15.60M17.34M
Selling, General & Administrative (Quarter)
21.62M21.42M21.30M20.83M19.07M21.63M24.47M22.49M21.75M24.55M27.30M30.06M28.94M34.86M34.97M43.20M37.58M39.35M51.49M48.44M
Operating Expenses (Quarter)
33.55M34.50M34.00M33.47M32.16M36.11M36.97M34.08M31.98M35.85M42.79M45.46M40.30M49.75M54.84M62.11M51.59M53.66M67.08M65.77M
Operating Income (Quarter)
-23.44M-19.91M-21.96M-18.71M-18.09M-20.28M-22.05M-15.38M-13.50M-14.61M-25.74M-25.84M-17.55M-27.66M-36.91M-41.45M-27.39M-19.11M-20.26M0.11M
EBIT (Quarter)
-23.44M-19.91M-21.96M-18.71M-18.09M-20.28M-22.05M-15.38M-13.50M-14.61M-25.74M-25.84M-17.55M-27.66M-36.91M-41.45M-27.39M-19.11M-20.26M0.11M
Non-operating items
Interest & Investment Income (Quarter)
0.06M0.02M-0.04M0.13M0.48M0.41M0.63M0.41M0.91M1.54M1.61M1.71M2.60M2.75M2.11M1.30M0.98M0.90M0.61M0.60M
Non Operating Income (Quarter)
-0.02M-0.08M-0.00M0.10M0.04M-0.06M-0.01M-0.03M0.07M
Net income details
EBT (Quarter)
-30.21M-27.32M-28.07M-26.66M-25.12M-28.18M-30.19M-24.08M-21.89M-22.16M-32.23M-33.37M-23.58M-34.86M-43.45M-48.92M-34.40M-26.64M-28.35M-8.72M
Tax Provisions (Quarter)
-25.47M0.33M0.03M0.71M-25.91M0.02M0.05M-0.01M-22.68M0.05M0.04M0.09M-28.71M0.39M1.01M-1.05M-35.64M-4.77M5.63M
Profit After Tax (Quarter)
-30.25M-28.48M-28.44M-26.69M-25.93M-28.82M-30.21M-24.14M-21.88M-26.02M-32.34M-33.40M-23.67M-37.51M-43.88M-49.95M-33.35M-26.37M-23.59M-14.36M
Income from Continuing Operations (Quarter)
-30.21M-1.85M-28.39M-26.69M-25.83M-2.27M-30.21M-24.14M-21.88M0.52M-32.29M-33.40M-23.67M-6.15M-43.84M-49.94M-33.35M9.00M-23.57M-14.35M
Consolidated Net Income (Quarter)
-30.21M-1.85M-28.39M-26.69M-25.83M-2.27M-30.21M-24.14M-21.88M0.52M-32.29M-33.40M-23.67M-6.15M-43.84M-49.94M-33.35M9.00M-23.57M-14.35M
Income towards Parent Company (Quarter)
-30.21M-1.85M-28.39M-26.69M-25.83M-2.27M-30.21M-24.14M-21.88M0.52M-32.29M-33.40M-23.67M-6.15M-43.84M-49.94M-33.35M9.00M-23.57M-14.35M
Net Income towards Common Stockholders (Quarter)
-30.21M-1.85M-28.39M-26.69M-25.83M-2.27M-30.21M-24.14M-21.88M0.52M-32.29M-33.40M-23.67M-6.15M-43.84M-49.94M-33.35M9.00M-23.57M-14.35M
Additional items
EPS (Basic) (Quarter)
-1.35-0.08-1.25-1.18-1.13-0.10-1.30-1.03-0.680.02-0.97-0.91-0.55-0.14-0.92-1.05-0.690.19-0.47-0.28
Shares Outstanding (Quarter)
22.38M22.35M22.63M22.70M22.80M22.81M23.28M23.46M32.30M28.83M33.38M36.82M43.10M42.88M47.42M47.74M48.06M48.12M50.18M50.38M
Shares Outstanding (Entity) (Quarter)
22.40M22.46M22.68M22.73M23.01M23.13M23.44M23.50M30.85M32.49M36.13M41.17M42.19M42.23M46.10M46.20M46.78M48.35M48.71M48.90M
EBITDA (Quarter)
-23.44M-19.91M-21.96M-18.71M-18.09M-20.28M-22.05M-15.38M-13.50M-14.61M-25.74M-25.84M-17.55M-27.66M-36.91M-41.45M-27.39M-19.11M-20.26M0.11M
Interest Expenses (Quarter)
-1.43M0.30M2.68M3.23M0.29M2.68M2.37M2.08M0.29M0.28M1.31M1.10M0.22M0.22M4.80M6.00M0.24M5.50M5.30M
Tax Rate (Quarter)
93.23%-1.16%-0.12%-2.82%91.96%-0.07%-0.22%0.04%102.34%-0.17%-0.11%-0.39%82.36%-0.90%-2.07%3.06%133.79%16.83%-64.54%